Systemic Therapies in the Treatment of Cutaneous T-cell Lymphoma

The treatment of Mycosis Fungoides (MF)/Sézary Syndrome (SS) is based on a multimodal approach through the involvement of different specialists including hematologists, dermatologists, and radiation therapists. The approach to the treatment combines different skin directed and systemic therapies (such as chemotherapies, immunomodulating agents, immunotherapies).

Although there are several well recognized therapies for the treatment of MF/SS, curative therapies are still needed. In this scenario, effective treatments that provide long term responses and disease control are still lacking. Also, International guidelines (EORTC 2017, ESMO 2018, BAD2018, NCCN) report treatment options for the different stages without recommendations of any order due to lack of evidence from clinical trials.

This study is designed to analyze the different approaches of systemic therapies for the treatment of Cutaneous T-cell Lymphoma in real world setting.

• To identify real life patients' baseline clinical characteristics (e.g. CTCL subtype, cutaneous, lymphatic and blood involvement (TNMB), staging). [Срок оценки: The endpoint will be evaluated from the beginning to the end of the study (up to 18 months)]
• Evaluate the effectiveness of each different systemic treatment trough evaluation of best ORR attained at any time (ORRb). [Срок оценки: The endpoint will be evaluated from the beginning to the end of the study (up to 18 months)]
• Overall Survival of enrolled patients. [Срок оценки: The endpoint will be evaluated from the beginning to the end of the study (up to 18 months)]
• Evaluate the safety of each different systemic treatments. [Срок оценки: The endpoint will be evaluated from the beginning to the end of the study (up to 18 months)]
• Impact of new drugs (brentuximab vedotin and mogamulizumab). [Срок оценки: The endpoint will be evaluated from the beginning to the end of the study (up to 18 months)]